KR970703137A - 배뇨장해 치료용 경피투여제제(percutaneously administrable preparation for treating urination disorder) - Google Patents

배뇨장해 치료용 경피투여제제(percutaneously administrable preparation for treating urination disorder) Download PDF

Info

Publication number
KR970703137A
KR970703137A KR1019960706510A KR19960706510A KR970703137A KR 970703137 A KR970703137 A KR 970703137A KR 1019960706510 A KR1019960706510 A KR 1019960706510A KR 19960706510 A KR19960706510 A KR 19960706510A KR 970703137 A KR970703137 A KR 970703137A
Authority
KR
South Korea
Prior art keywords
molecular weight
drug
transdermal
urination
agent
Prior art date
Application number
KR1019960706510A
Other languages
English (en)
Inventor
가츠히로 나카무라
노부유키 고가
Original Assignee
나카토미 히로타카
히사미츠 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나카토미 히로타카, 히사미츠 세이야쿠 가부시키가이샤 filed Critical 나카토미 히로타카
Publication of KR970703137A publication Critical patent/KR970703137A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

배뇨장해치료약을 저분자량 폴리이소부틸렌, 고분자량 폴리이소부틸렌 및 유지를 주기제로 함유하는 점착제 중에 함유시켜서 구성되는 배뇨장해치료용 경피투여제제이다. 또, 배뇨장해 치료약은 저분자량 폴리이소부틸렌, 고분자량 폴리이소부틸렌, 유지 및 스티렌이소프렌스티렌블록 공중합체를 주기제로 함유하는 점착제중에 함유시켜서 구성되는 배뇨장해치료용 경피투여제제이다. 본 발명의 배뇨장해치료용 경피투여제제는 이와 같은 특정 기제성분을 사용함으로써 경시적 안정성이 우수하고, 피부에 대해여 저자극성이고, 게다가 경피흡수성에도 우수하다.

Description

배뇨장해 치료용 경피투여제제(PERCUTANEOUSLY ADMINISTRABLBLE PREPARATION FOR TREATING URINATION DISORDER)
[도면의 간단한 설명]
제1도는 래트에 의한 경피흡수시험결과를 도시한다,
제2도는 사람 피부에 의한 경피흡수시험결과를 도시한다,
제1도 및 제2도에 있어서, ○은 하기의 실시예 1의 제제, ●은 하기 실시예 2의 제제, □은 하기 실시예 3의 제제, ■은 하기 실시예 4의 제제, ◇은 하기 실시예 5의 제제, ×는 하기 실시예 6의 제제,은 하기 실시예 7의 제제, ◆은 하기 비교예 1의 제제, △은 하기 비교예 2의 제제, □은 하기 비교예 3의 제제, |은 하기 비교예 4의 제제,은 하기 비교예 19의 제제,비교예 20의 제제의 결과를 나타낸다.
제3도는 래트에 의한 시스토메트리법에 의한 약효 평가시험 결과를 도시한다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 배뇨장해 치료약을 저분자량 폴리이소부틸렌, 고분자량 폴리이소부틸렌 및 유지를 주기제로서 함유하는 점착제중에 함유시켜서 구성되는 배뇨장해 치료용 경피투여제제.
  2. 제1항에 있어서, 상기 점착제의 전체중량에 의거하여, 상기 배뇨장해치료약 0.01∼50중량부를 상기 저분자량 폴리이소부틸렌 1∼60중량부, 상기 고분자량 폴리이소부틸렌 0.1∼40중량부 및 상기 유지 10∼60중량부를 주기제로서 함유하는 점착제중에 함유시켜서 구성되는 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  3. 배뇨장해치료약을 저분자량 폴리이소부틸렌, 고분자량 폴리이소부틸렌, 유지 및 스티렌이소프렌스티렌블록 공중합체를 주기제로 함유하는 점착제중에 함유시켜서 구성되는 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  4. 제3항에 있어서, 상기 점착제의 전체중량에 의거하여, 상기 배뇨장해치료약 0.01∼50중량부를 상기 저분자량 폴리이소부틸렌 1∼60중량부, 상기 고분자량 폴리이소부틸렌 0.1∼40중량부, 상기 유지 10∼60중량부 및 상기 스티렌이소프렌스티렌블록 공중합체 5∼50중량부를 주기제로 함유하는 점착제중에 함유시켜서 구성되는 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 배뇨장해치료약이 요실금치료약, 배뇨곤란치료약, 빈뇨치료약 또는 배뇨통 치료약인 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  6. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 배뇨장해치료약이 요실금치료약인 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  7. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 저분자량 폴리이소부틸렌의 점도평균 분자량이 10,000∼100,000이고, 상기 고분자량 폴리이소부틸렌의 점도평균 분자량이 500,000∼2,500,000인 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  8. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 유지가 점도 5∼100mm2/S의 유동 파라핀, 천연 및 합성 스쿠알렌 및 스쿠알란으로 이루어지는 군에서 선택된 적어도 1종인 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
  9. 제l항 내지 제8항 중 어느 한 항에 있어서, 경피흡수촉진제를 더 포함하는 것을 특징으로 하는 배뇨장해 치료용 경피투여제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960706510A 1994-05-18 1995-05-18 배뇨장해 치료용 경피투여제제(percutaneously administrable preparation for treating urination disorder) KR970703137A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12816294 1994-05-18
JP94-128162 1994-05-18
PCT/JP1995/000946 WO1995031190A1 (fr) 1994-05-18 1995-05-18 Preparation administrable par voie percutanee pour le traitement des troubles de la miction

Publications (1)

Publication Number Publication Date
KR970703137A true KR970703137A (ko) 1997-07-03

Family

ID=14977927

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960706510A KR970703137A (ko) 1994-05-18 1995-05-18 배뇨장해 치료용 경피투여제제(percutaneously administrable preparation for treating urination disorder)

Country Status (8)

Country Link
US (1) US5770221A (ko)
EP (1) EP0760238B1 (ko)
KR (1) KR970703137A (ko)
AU (1) AU2454495A (ko)
DE (1) DE69526437T2 (ko)
DK (1) DK0760238T3 (ko)
ES (1) ES2172584T3 (ko)
WO (1) WO1995031190A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
JP4073517B2 (ja) * 1997-04-07 2008-04-09 久光製薬株式会社 経皮吸収貼付剤用粘着剤及び経皮吸収貼付剤
DE69939019D1 (de) * 1998-07-07 2008-08-14 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
AU2940000A (en) * 1999-03-11 2000-09-28 Mitsubishi Chemical Corporation Drug composition for percutaneous absorption
AU3536799A (en) * 1999-04-26 2000-11-10 Lead Chemical Co., Ltd. Percutaneous preparations containing oxybutynin
WO2001010436A1 (fr) * 1999-08-09 2001-02-15 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees au traitement de l'uropathie inferieur
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
CN1235572C (zh) * 1999-12-15 2006-01-11 久光制药株式会社 贴剂
ES2367541T3 (es) 2000-04-18 2011-11-04 Hisamitsu Pharmaceutical Co., Inc. Parche que contiene un agente antiinflamatorio.
JP2001328935A (ja) * 2000-05-19 2001-11-27 Hisamitsu Pharmaceut Co Inc 貼付剤
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
JP4394443B2 (ja) * 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
TWI296531B (en) * 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
EP1652523A4 (en) * 2003-08-04 2008-11-19 Kyorin Seiyaku Kk PREPARATION FOR TRANSDERMAL ABSORPTION
JP4593471B2 (ja) * 2003-10-20 2010-12-08 久光製薬株式会社 皮膚外用貼付剤
DE10357321A1 (de) * 2003-12-05 2005-07-21 Tesa Ag Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
DE102004009903A1 (de) * 2004-02-26 2005-09-22 Grünenthal GmbH Pflaster mit reduzierter Hautirritation
JP5208348B2 (ja) * 2004-05-13 2013-06-12 旭化成ファーマ株式会社 ナフトピジルを含有する医薬
EP1844773A4 (en) * 2005-02-03 2010-04-28 Kyorin Seiyaku Kk PREPARATION FOR PERCUTANEOUS ABSORPTION
EP1878429B1 (en) * 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
JP4921739B2 (ja) * 2005-08-10 2012-04-25 久光製薬株式会社 皮膚刺激を低減した貼付剤
JP4913738B2 (ja) * 2005-08-19 2012-04-11 ダイヤ製薬株式会社 プラスターの製造方法及びその製造装置及びプラスター用ライナー
WO2007119656A1 (ja) 2006-04-11 2007-10-25 Nichiban Co., Ltd. タムスロシン含有経皮吸収型製剤
US20100092544A1 (en) * 2008-10-14 2010-04-15 Katsuhiro Okada Adhesive composition for patch and use thereof
US20150030666A1 (en) * 2011-11-28 2015-01-29 KM Transderm Ltd. Adhesive skin patch
EP3228309A4 (en) * 2014-12-05 2018-07-11 KM Transderm Ltd. Adhesive sheet for attachment to skin and percutaneous absorption preparation using same
WO2018026371A1 (en) * 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
DE3344691A1 (de) * 1983-12-10 1985-06-20 Bayer Ag, 5090 Leverkusen Wirkstoffabgasesysteme
JPS6145052A (ja) * 1984-08-07 1986-03-04 有限会社 ▲カゲ▼山商事 桟瓦
EP0204968B1 (de) * 1985-05-24 1989-09-27 Beiersdorf Aktiengesellschaft Nitro-Pflaster
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4793337A (en) * 1986-11-17 1988-12-27 E. R. Squibb & Sons, Inc. Adhesive structure and products including same
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
JPH0725669B2 (ja) * 1988-12-23 1995-03-22 日東電工株式会社 経皮投与用医薬製剤
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
JP2869167B2 (ja) * 1990-08-09 1999-03-10 日東電工株式会社 徐放性貼付製剤
JP3136413B2 (ja) * 1991-02-22 2001-02-19 リードケミカル株式会社 経皮吸収型頻尿・尿失禁治療剤
JPH04273818A (ja) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd 経皮投与製剤
AU666735B2 (en) * 1992-05-13 1996-02-22 Alza Corporation Transdermal administration of oxybutynin
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents

Also Published As

Publication number Publication date
EP0760238A4 (en) 1998-06-03
EP0760238B1 (en) 2002-04-17
DE69526437T2 (de) 2002-10-31
EP0760238A1 (en) 1997-03-05
DE69526437D1 (de) 2002-05-23
DK0760238T3 (da) 2002-07-22
US5770221A (en) 1998-06-23
WO1995031190A1 (fr) 1995-11-23
AU2454495A (en) 1995-12-05
ES2172584T3 (es) 2002-10-01

Similar Documents

Publication Publication Date Title
KR970703137A (ko) 배뇨장해 치료용 경피투여제제(percutaneously administrable preparation for treating urination disorder)
Kita et al. Drugs used to treat spasticity
Gros Spasticity—clinical classification and surgical treatment
KR0143916B1 (ko) 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법
Suputtitada et al. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity
US5612382A (en) Composition for percutaneous absorption of pharmaceutically active ingredients
Botte et al. Treatment of acquired muscle spasticity using phenol peripheral nerve blocks
IE892680L (en) A new method of treating erectile dysfunction
BR9812134A (pt) Composição farmacêutica para tratamento de dismenorréia e parto prematuro
Esquenazi et al. Instrumented assessment of muscle overactivity and spasticity with dynamic polyelectromyographic and motion analysis for treatment planning
BR9714270A (pt) Composição lìquida de limpeza de pele
WO1998031339A1 (en) Skin preparation
EP0266968A2 (en) Gelled ointment of vasodilating agent
US20070048386A1 (en) Medicament for treating inflammatory and non-inflammatory arthritis
BR9912508A (pt) Métodos e composições transdérmicas para alìvio da dor
Toğrol et al. Bilateral peroneal nerve palsy induced by prolonged squatting
IL95820A (en) Preparations for the treatment of inflammatory or allergic painful physical defects containing SIC-8-methyl-N- and anilyl-6-nonanamide
KR950028767A (ko) 피부통과 투약을 위한 신규의 약제학적 투여 형태
WO1999038472A2 (en) Topical vasodilatory gel composition and methods of use and production
AU7069000A (en) Apparatus and method for anesthetizing the cervical region of a female
Clarke Effectiveness of rehabilitation in arthritis
EP0873751A3 (en) Pharmaceutical product for application to uterus mucosa
Young et al. Current issues in spasticity management
Dietz et al. The syndrome of spastic paresis
ES2074402A1 (es) Formulacion farmaceutica conteniendo difenhidramina, talco, calamina y extracto de avena, en una base emulsionada, y sus aplicaciones.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application